Epivax

The Gloria Gemma Breast Cancer Resource Foundation is a non-profit organization dedicated to providing free support, education, and wellness services to individuals and families affected by breast cancer in Rhode Island, southeastern Massachusetts, and eastern Connecticut. With a mission to celebrate and nurture life before, during, and after a cancer diagnosis, the foundation offers a wide range of holistic programs and resources to help restore the mind, body, and spirit of those impacted by cancer.Generated from the website

An immuno-competent skin model is among the products under development from MatTek Corporation. The company is one of the worldwide industry leaders in tissue engineering. MatTek produces normal (non-transformed), human cell-derived, 3-D organotypic in vitro tissue models for use in product development/efficacy, claims substantiation, safety assessment and target organ research applications. The creative use of non-animal (in vitro) testing was fueled by the synergistic effect of lower (direct/indirect) costs and improved product quality. MatTek reduced product cost and increased lab efficiency by delivering reproducible products. Located in Ashland, Mass., MatTek Corporation was founded in 1985 by two chemical engineering professors from the Massachusetts Institute of Technology.

Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of pharmaceutical products directed toward serving unmet medical needs. The company s drug development program has yielded a portfolio of pharmaceutical compounds with a focus on respiratory and central nervous system disorders. Its commercialization efforts are carried out by a United States-based nearly 1,250-person primary care and specialty sales force through co-promotion agreements and through out-licensing partnerships. Sunovion Pharmaceuticals selects development compounds with the potential to offer improvements over existing therapies with respect to efficacy, side-effect profile, dosage forms and, in some cases, the opportunity for additional indications. The focus of its discovery effort is to identify additional drug candidates that are directed toward treating respiratory and central nervous system disorders. These compounds are expected to complement Sunovion Pharmaceuticals pharmaceutical pipeline. Sunovion Pharmaceuticals is headquartered n Marlborough, Mass.